Publication Name	World Journal of Pharmacology
Manuscript ID	12447
Country	United States

Received	2014-07-09 08:40
Peer-Review Started	2014-07-09 09:34
To Make the First Decision	2014-08-14 14:26
Return for Revision	2014-08-19 16:13
Revised	2014-09-03 20:16
Second Decision	2015-01-14 09:14
Accepted by Journal Editor-in-Chief	2015-01-16 18:05
Accepted by Executive Editor-in-Chief	2015-01-20 16:34
Articles in Press	2015-01-20 16:35
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-02-28 10:09
Publish the Manuscript Online	2015-03-12 19:39

ISSN	2220-3192 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Pharmacology & Pharmacy
Manuscript Type	Review
Article Title	Levomilnacipran and vortioxetine: Review of new pharmacotherapies for major depressive disorder
Manuscript Source	Invited Manuscript
All Author List	Mei T Liu, Megan E Maroney and Evelyn R Hermes-DeSantis
Funding Agency and Grant Number
Corresponding Author	Mei T Liu, PharmD, BCPP, Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, United States. mei_liu@pharmacy.rutgers.edu
Key Words	Levomilnacipran; Vortioxetine; Adult; Major depressive disorder; Antidepressive agents
Core Tip	Levomilnacipran and vortioxetine are the two newest antidepressant medications to join the armamentarium of treatment choices for major depressive disorder. Levomilnacipran, a serotonin norepinephrine reuptake inhibitor, is an enantiomer of the previously approved fibromyalgia agent milnacipran. Vortioxetine is a multimodal antidepressant with a unique mechanism of action, affecting several serotonin receptors as well as inhibiting serotonin reuptake. This review summarizes the clinical trial data as well as pharmacokinetic, dosing and safety concerns with these two new agents.
Publish Date	2015-03-12 19:39
Citation	Liu MT, Maroney ME, Hermes-DeSantis ER. Levomilnacipran and vortioxetine: Review of new pharmacotherapies for major depressive disorder. World J Pharmacol 2015; 4(1): 17-30
URL	http://www.wjgnet.com/2220-3192/full/v4/i1/17.htm
DOI	http://dx.doi.org/10.5497/wjp.v4.i1.17

Full Article (PDF)	WJP-4-1.pdf
Full Article (Word)	WJP-4-1.doc
Manuscript File	12447-Review.docx
Answering Reviewers	12447-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	12447-Conflict-of-interest statement.pdf
Copyright License Agreement	12447-Copyright assignment.pdf
Peer-review Report	12447-Peer review(s).pdf
Scientific Misconduct Check	12447-CrossCheck.jpg
Scientific Editor Work List	12447-Scientific editor work list.pdf